Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.1 -0.01 (-0.9%) Market Cap: 281.12 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 11.00 GF Score: 66/100

Adaptimmune Therapeutics PLC to Provide Clinical and Business Update Call Transcript

May 06, 2019 / 12:00PM GMT
Release Date Price: $4.37 (-5.82%)
Operator

Good day, ladies and gentlemen, and welcome to the Adaptimmune Clinical and Business Update. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Ms. Juli Miller. You may begin.

Juli P. Miller
Adaptimmune Therapeutics plc - Director of IR

Hi, good morning, and welcome to Adaptimmune's webcast during which we will summarize our most recent clinical data and next steps for the company. We will present slides during this webcast, and there is a link to join on the IR tab of our website. The link is also available in the press release we issued at 7:00 a.m. this morning that provides an overview of our clinical update. The slides are available on the IR tab of our website for your reference as well.

Earlier this morning, we issued two press releases, one detailing our most recent clinical data and a second providing updated financial information based on our Q1 2019 results. To be clear, this morning's webcast will focus on our latest clinical data and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot